Equibles does not estimate personal net worth.
Get an email with a short summary when Tarsus Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get TARS alertsBobak Azamian is recorded as Chairman at Tarsus Pharmaceuticals, Inc. (TARS) since December 2, 2022 and CEO at Tarsus Pharmaceuticals, Inc. (TARS). The newest filing on record that lists Bobak Azamian as CEO at Tarsus Pharmaceuticals, Inc. (TARS) is dated April 28, 2026. Tarsus Pharmaceuticals, Inc. reported in an 8-K filed December 7, 2022 that Bobak Azamian was appointed Chairperson of the Board, effective December 2, 2022. The proxy statement of Tarsus Pharmaceuticals, Inc. reports total compensation of $6,617,979 for Bobak Azamian in fiscal 2025, including a base salary of $726,333. Disclosed compensation is on record for 7 fiscal years. Bobak Azamian has spoken on 2 earnings calls across 1 company, most recently for Tarsus Pharmaceuticals, Inc. on May 8, 2024. Tarsus Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Tarsus Pharmaceuticals, Inc. includes Jeffrey S. Farrow (CFO), Leonard Greenstein (CFO), Seshadri Neervannan (COO) and 7 others.
“the Board authorized and approved the appointment of Bobak Azamian, the Company's Chief Executive Officer and current member of the Board, as Chairperson of the Board, and Wendy Yarno, current member of the Board, as Lead Independent Director, each appointment effective as of December 2, 2022.”
“2024 is off to a great start for Tarsus, and I'm excited to share our progress with you today. We continue to build and grow a new category with exceptional commercial performance and make strides to do it again with the advancement of our pipeline.”
“Thank you, Dave, and thank you all for joining us for our first-ever earnings call, and our first opportunity to speak with you since the highly anticipated launch of XDEMVY, the only FDA-approved treatment for Blepharitis.”
2022-12-02–present
Start not stated–present
Last confirmed April 28, 2026
Start not stated–2022-05-02
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
CEO, Chairman
2022-12-02–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Tarsus Pharmaceuticals, Inc. (TARS) | M.D., Ph.D. President, Chief Executive Officer and Board Chairman | $726,333 | $6,617,979 |
| 2024 | Tarsus Pharmaceuticals, Inc. (TARS) | M.D., Ph.D. President, Chief Executive Officer and Board Chairman | $673,400 | $7,896,192 |
| 2023 | Tarsus Pharmaceuticals, Inc. (TARS) | M.D., Ph.D. President, Chief Executive Officer and Board Chairman | $619,500 | $3,130,332 |
| 2022 | Tarsus Pharmaceuticals, Inc. (TARS) | M.D., Ph.D. President, Chief Executive Officer and Board Chairman | $590,000 | $3,916,280 |
| 2021 | Tarsus Pharmaceuticals, Inc. (TARS) | M.D., Ph.D. President, Chief Executive Officer and Board Chairman | $550,000 | $6,870,723 |
| 2020 | Tarsus Pharmaceuticals, Inc. (TARS) | M.D., Ph.D. President, Chief Executive Officer and Director | $437,000 | $2,510,396 |
| 2019 | Tarsus Pharmaceuticals, Inc. (TARS) | M.D. Ph.D. President, Chief Executive Officer and Director | $300,000 | $416,137 |
